PT Bundamedik Tbk (ISX:BMHS) Change In Receivables: Rp Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:BMHS PT Bundamedik Tbk ISX:BMHS
76 GF Score
Price Rp200.00
GF Value Rp278.84
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is PT Bundamedik Tbk Change In Receivables?

PT Bundamedik Tbk ISX:BMHS +1.01% 76 Change In Receivables is Rp Mil as of Jun. 2026. GuruFocus rates ISX:BMHS with a GF Score™ of 76/100 and a GF Value™ of Rp278.84 (Modestly Undervalued). The stock has 6 warning signs investors should review.

PT Bundamedik Tbk's change in receivables for the quarter that ended in Jun. 2026 was Rp Mil. It means PT Bundamedik Tbk's Accounts Receivable stayed the same from Mar. 2026 to Jun. 2026 .

PT Bundamedik Tbk's change in receivables for the fiscal year that ended in Dec. 2025 was Rp Mil. It means PT Bundamedik Tbk's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

PT Bundamedik Tbk's Accounts Receivable for the quarter that ended in Jun. 2026 was Rp181,990 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. PT Bundamedik Tbk's Days Sales Outstanding for the three months ended in Jun. 2026 was 41.89.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. PT Bundamedik Tbk's liquidation value for the three months ended in Jun. 2026 was Rp-742,488 Mil.

PT Bundamedik Tbk  (ISX:BMHS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

PT Bundamedik Tbk's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=181990.440952/396451.026427*91
=41.89

2. In Ben Graham's calculation of liquidation value, PT Bundamedik Tbk's accounts receivable are only considered to be worth 75% of book value:

PT Bundamedik Tbk's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=842313.621103-1745491.326902+0.75 * 181990.440952+0.5 * 48392.762932
=-742,488

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Bundamedik Tbk Change In Receivables Related Terms

PT Bundamedik Tbk Change In Receivables Historical Data

* Premium members only.

The historical data trend for PT Bundamedik Tbk's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Bundamedik Tbk Change In Receivables Chart

PT Bundamedik Tbk Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial - - - - -

PT Bundamedik Tbk Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
ISX:BMHS
76GF Score
PT Bundamedik Tbk ISX:BMHS
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Bundamedik Tbk Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of Rp Mil mean?
PT Bundamedik Tbk (ISX:BMHS) has a Change In Receivables of Rp Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for PT Bundamedik Tbk and its competitors.
Is PT Bundamedik Tbk's Change In Receivables too high?
PT Bundamedik Tbk's current Change In Receivables is Rp Mil. Overall, PT Bundamedik Tbk has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Bundamedik Tbk's Change In Receivables compare to HCA and THC?
PT Bundamedik Tbk's Change In Receivables of Rp Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Healthcare Providers & Services company?
A good Change In Receivables depends on the Healthcare Providers & Services industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for PT Bundamedik Tbk and its competitors. PT Bundamedik Tbk's current Change In Receivables is Rp Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Bundamedik Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Bundamedik Tbk (ISX:BMHS) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp278.84, compared to a current price of Rp200.00 — trading 28.3% below its estimated fair value. The current Change In Receivables is Rp Mil. PT Bundamedik Tbk's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For PT Bundamedik Tbk (ISX:BMHS), the current Change In Receivables is Rp Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Bundamedik Tbk (ISX:BMHS) Overvalued in 2026?

Based on GuruFocus' analysis, PT Bundamedik Tbk stock appears to be undervalued. The current stock price of Rp200.00 is trading 28.3% below its estimated GF Value™ of Rp278.84. GuruFocus considers PT Bundamedik Tbk to be Modestly Undervalued.

Key valuation signals for ISX:BMHS:

  • Change In Receivables: Rp Mil
  • GF Value™: Rp278.84 vs. price of Rp200.00 (28.3% below fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the ISX:BMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Bundamedik Tbk Business Description

Address Jalan Teuku Cik Ditiro No.28, Menteng, Jakarta Pusat, IDN, 10350
PT Bundamedik Tbk is a healthcare service provider. The Company carries out its main business activities through private hospital activities. It offers maternal and child health services, outpatient services, inpatient services, emergency services, service excellence centers, IVF services, and Clinical laboratory services.
76GF Score

Get the complete analysis for ISX:BMHS

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp200.00
Price
Rp278.84
GF Value